Illumina faces low-cost rival as BGI touts sub $100 gene sequencing

Chinese sequencing giant BGI is squaring up against Illumina (NASDAQ:ILMN) as Complete Genomics, an independent company whose parent is BGI, announced Tuesday the market launch of a new class of low-cost sequencers, it says, could cut the genome sequencing price to sub $100.